tiprankstipranks
Trending News
More News >

Solasia Pharma Reports Q1 Results and Pipeline Updates

Story Highlights
Solasia Pharma Reports Q1 Results and Pipeline Updates

Don’t Miss TipRanks’ Half-Year Sale

An announcement from Solasia Pharma KK ( (JP:4597) ) is now available.

Solasia Pharma K.K. reported its consolidated financial results for the first quarter of the fiscal year ending December 31, 2025, and provided updates on its major pipeline products. The company has faced a decline in sales of Sancuso in China due to shipment constraints following a manufacturing facility transfer. Meanwhile, DARVIAS, used for treating peripheral T-cell lymphoma, has seen progress with marketing rights out-licensed in Japan and South America, with ongoing regulatory approval processes in countries like Colombia and Peru.

More about Solasia Pharma KK

Solasia Pharma K.K. operates in the pharmaceutical industry, focusing on the development and commercialization of oncology treatments. The company is involved in the production of products like Sancuso, a transdermal delivery system for chemotherapy-induced nausea, and DARVIAS, an organic arsenic compound for treating peripheral T-cell lymphoma.

Average Trading Volume: 4,341,935

Technical Sentiment Signal: Sell

Current Market Cap: Yen7.02B

Learn more about 4597 stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1